Should I Buy DBD? DBD 2026 Analysis

Should You Buy Diebold Nixdorf Inc (DBD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

71.810

1 Day change

3.55%

52 Week Range

72.530

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient entry: near-term odds skew negative (pattern stats show -2.78% next week, -4.66% next month) with earnings on 2026-02-12 pre-market.
Trend is mixed: longer-term moving averages are bullish, but momentum is weakening (MACD histogram negative and expanding) and price is below the 69.755 pivot pre-market.
Sentiment is conflicted: hedge funds are accumulating aggressively (+200.38% QoQ buying), while insiders are selling heavily (+113.75% MoM), which is a near-term negative.
Options positioning is unusual into earnings (very low OI put/call but slightly put-leaning volume), plus elevated IV percentile—suggesting event risk is being priced.
Intellectia Proprietary Trading Signals
- AI Stock Picker: No signal on given stock today.
- SwingMax: No signal on given stock today.

Technical Analysis

Price context: pre-market ~69.38 (near pivot 69.755); immediate support 67.62 then 66.30; resistance 71.89 then 73.21.
Moving averages: Bullish stack (SMA_5 > SMA_20 > SMA_200) suggests the bigger picture trend has been up.
Momentum: MACD histogram -0.0882 and negatively expanding = bearish/weakening momentum despite bullish MAs.
RSI(6) 45.15 = neutral-to-slightly weak; not oversold (no strong bounce signal).
Practical read: setup looks like “uptrend losing steam” into a catalyst window; not ideal for a buy-now, need-it-to-work-immediately entry.

Options Data

Bullish

Open Interest Put-Call Ratio

Neutral

Option Volume Put-Call Ratio

Open interest: Calls 245 vs puts 27 (OI put/call 0.11) = positioning heavily call-skewed.
Volume today: 39 contracts with put/call volume ratio 1.05 (puts slightly > calls on the day) = near-term hedging/tactical caution.
Activity spike: today’s volume ~390% of 30-day average; today vs OI avg 30D ~132.68% = elevated attention, consistent with pre-earnings positioning.
Volatility: IV30 ~49.79 vs historical vol ~30.77; IV percentile 67.6 = options are pricing a larger-than-usual move (event risk premium).
Net takeaway: options market is pricing meaningful earnings risk; not a clean bullish sentiment read despite call-heavy OI.

Technical Summary

Sell

Buy

Positive Catalysts

- Industry/news tailwind: increasing retailer investment in AI-driven self-checkout and hybrid checkout models could support demand for DBD’s solutions.
- Technical backdrop (longer-term): bullish moving-average structure can attract trend-following buyers if momentum re-accelerates.
- Institutional flow: hedge funds are net buyers with a sharp increase in buying over the last quarter (+200.38%).

Neutral/Negative Catalysts

- Earnings catalyst risk: QDEC 2025 earnings due 2026-02-12 pre-market (EPS est. 1.73); with elevated IV, market is expecting a sizable move.
- Insider activity: insiders are selling, with selling up +113.75% over the last month.
- Momentum deterioration: MACD histogram below zero and worsening; price is also below the pivot level pre-market.
- Statistical near-term bias: similar-pattern projection shows negative skew for the next week/month.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: 945.2M, +1.95% YoY (modest growth).
Profitability: Net income 41.1M, -283.48% YoY; EPS 1.11, -285.00% YoY (sharp decline vs prior year, suggesting either margin pressure and/or prior-year one-offs).
Gross margin: 26.23%, +0.58% YoY (slight improvement, but not enough to offset the earnings decline).
Bottom line: top-line is steady, but earnings volatility is high—making a buy right before the next earnings release less attractive for a quick-win entry.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating changes or price target updates were provided in the data, so the current Wall Street trend cannot be confirmed.
Wall Street-style pros (from available info): structural demand tailwinds in self-service/AI checkout; modest revenue growth; hedge fund accumulation.
Wall Street-style cons (from available info): large YoY EPS/net income drop; insiders selling; weakening momentum into earnings; options implying elevated event risk.
Politicians/influential figures: no recent congress trading data available in the last 90 days.

2 Analyst Rating

Wall Street analysts forecast DBD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DBD is 80 USD with a low forecast of 80 USD and a high forecast of 80 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 69.350

Low

Averages

High

Current: 69.350

Low

Averages

High

Wedbush

Antoine Legault

Outperform

maintain

$60 -> $70

AI Analysis

2025-08-07

Reason

Wedbush

Antoine Legault

Price Target

$60 -> $70

AI Analysis

2025-08-07

maintain

Outperform

Reason

Wedbush analyst Antoine Legault raised the firm's price target on Diebold to $70 from $60 and keeps an Outperform rating on the shares. In the firm's view, the better Q2 results combined with effective tariff mitigation and LEAN initiatives, a strong backlog, and good visibility into forward revenues all lend further credence to management's decision to not only maintain its guide, but to narrow the range towards the high end of its prior full year outlook.

Wedbush

Antoine Legault

Outperform

initiated

$60

2025-07-22

Reason

Wedbush

Antoine Legault

Price Target

$60

2025-07-22

initiated

Outperform

Reason

Wedbush assumed Antoine Legault initiated coverage of Diebold with an Outperform rating and $60 price target. Heading into Q2 earnings, the firm believes that backlog and cash flow figures will be in focus, as well as any potential impacts from a weaker USD, changing tariff policies, and order pull-ins. Wedbush will also look for further management commentary and updates around signs pointing to uptick in orders driven by the beginning of a refresh cycle, and progression or shifts to a services model and/or increased software traction and value-add.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DBD

Unlock Now

DBD Should I Buy

DBD Should I Buy

Should You Buy Diebold Nixdorf Inc (DBD) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch